EUVIMEDEUVIMED entdecken
Crossref

Increasing Linker Chain Length and Intestinal Stability Enhances Lymphatic Transport and Lymph Node Exposure of Triglyceride Mimetic Prodrugs of a Model Immunomodulator Mycophenolic Acid

Sifei Han iD, Tim Quach, Luojuan Hu, Shea Fern Lim, Dan Zheng, Nathania J Leong, Garima Sharma, Daniel Bonner, Jamie S Simpson, Natalie L Trevaskis iD, Christopher J H Porter iD

Molecular Pharmaceutics · 01.05.2023 · 20 (5) · 2675-2685

DOI: 10.1021/acs.molpharmaceut.3c00099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 30.03.2023. Verfasst von Sifei Han und 10 weiteren Autor:innen. Beteiligte Einrichtung: PureTech Health, 6 Tide Street, Boston, Massachusetts 02210, United States. Hauptthemen laut MEDLINE: Prodrugs. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Health and Medical Research Council, Australian Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted delivery of immunomodulators to the lymphatic system has the potential to enhance therapeutic efficacy by increasing colocalization of drugs with immune targets such as lymphocytes. A triglyceride (TG)-mimetic prodrug strategy has been recently shown to enhance the lymphatic delivery of a model immunomodulator, mycophenolic acid (MPA), via incorporation into the intestinal TG deacylation-reacylation and lymph lipoprotein transport pathways. In the current study, a series of structurally related TG prodrugs of MPA were examined to optimize structure-lymphatic transport relationships for lymph-directing lipid-mimetic prodrugs. MPA was conjugated to the sn-2 position of the glyceride backbone of the prodrugs using linkers of different chain length (5-21 carbons) and the effect of methyl substitutions at the alpha and/or beta carbons to the glyceride end of the linker was examined. Lymphatic transport was assessed in mesenteric lymph duct cannulated rats, and drug exposure in lymph nodes was examined following oral administration to mice. Prodrug stability in simulated intestinal digestive fluid was also evaluated. Prodrugs with straight chain linkers were relatively unstable in simulated intestinal fluid; however, co-administration of lipase inhibitors (JZL184 and orlistat) was able to reduce instability and increase lymphatic transport (2-fold for a prodrug with a 6-carbon spacer, i.e., MPA-C6-TG). Methyl substitutions to the chain resulted in similar trends in improving intestinal stability and lymphatic transport. Medium- to long-chain spacers (C12, C15) between MPA and the glyceride backbone were most effective in promoting lymphatic transport, consistent with increases in lipophilicity. In contrast, short-chain (C6-C10) linkers appeared to be too unstable in the intestine and insufficiently lipophilic to associate with lymph lipid transport pathways, while very long-chain (C18, C21) linkers were also not preferred, likely as a result of increases in molecular weight reducing solubility or permeability. In addition to more effectively promoting drug transport into mesenteric lymph, TG-mimetic prodrugs based on a C12 linker resulted in marked increases (>40 fold) in the exposure of MPA in the mesenteric lymph nodes in mice when compared to administration of MPA alone, suggesting that optimizing prodrug design has the potential to provide benefit in targeting and modulating immune cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsRatsMiceAnimalsTriglyceridesMycophenolic AcidLymph NodesIntestinesGlyceridesImmunologic FactorsAdjuvants, ImmunologicAdministration, Oral

Stichwörter der Autor:innen

lipid-based formulationlymphatic transportmycophenolic acidoral drug deliveryprodrugtriglyceride mimetic

Substanzen

ProdrugsTriglyceridesMycophenolic AcidGlyceridesImmunologic FactorsAdjuvants, Immunologic

Autor:innen und Institutionen

  • PureTech Health, 6 Tide Street, Boston, Massachusetts 02210, United States.

ORCID-Profile: Sifei Han, Natalie L Trevaskis, Christopher J H Porter

Förderung

  • National Health and Medical Research Council
  • Australian Research Council

Zitieren

APA

Han, S., Quach, T., Hu, L., Lim, S. F., Zheng, D., Leong, N. J., Sharma, G., Bonner, D., Simpson, J. S., Trevaskis, N. L., & Porter, C. J. H. (2023). Increasing Linker Chain Length and Intestinal Stability Enhances Lymphatic Transport and Lymph Node Exposure of Triglyceride Mimetic Prodrugs of a Model Immunomodulator Mycophenolic Acid. Molecular Pharmaceutics, 20(5), 2675-2685. https://doi.org/10.1021/acs.molpharmaceut.3c00099

Vancouver

Han S, Quach T, Hu L, Lim SF, Zheng D, Leong NJ, et al. Increasing Linker Chain Length and Intestinal Stability Enhances Lymphatic Transport and Lymph Node Exposure of Triglyceride Mimetic Prodrugs of a Model Immunomodulator Mycophenolic Acid. Molecular Pharmaceutics. 2023;20(5):2675-2685. doi:10.1021/acs.molpharmaceut.3c00099

BibTeX
@article{Han2023,
  author = {Han, Sifei and Quach, Tim and Hu, Luojuan and Lim, Shea Fern and Zheng, Dan and Leong, Nathania J and Sharma, Garima and Bonner, Daniel and Simpson, Jamie S and Trevaskis, Natalie L and Porter, Christopher J H},
  title = {Increasing Linker Chain Length and Intestinal Stability Enhances Lymphatic Transport and Lymph Node Exposure of Triglyceride Mimetic Prodrugs of a Model Immunomodulator Mycophenolic Acid},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  volume = {20},
  number = {5},
  pages = {2675--2685},
  doi = {10.1021/acs.molpharmaceut.3c00099}
}
Kostenlos starten →